BACKGROUND: We previously reported on the change in the use of @entity6170 -containing products (RCP) and adverse event reporting rates in Canadian @entity1 between 2004 and 2010. The present study extends this analysis to include the January 2011 to December 2012 time period. METHODS: RCP utilization rates were obtained from IMS Health Brogan's longitudinal de-identified @entity1 database, LRx. GlaxoSmithKline's global adverse events database was used to extract adverse events (AE), serious adverse events (SAE), and @entity299 ( @entity299 ) reported in Canadian @entity1 receiving RCP from April 2004 to December 2012. The @entity1 utilization information from the LRx database was used to estimate rates per 100,000 @entity1 . RESULTS: An estimated 182,841 @entity1 were dispensed RCP prescriptions between April 2004 and December 2012. The total number of @entity1 using RCP decreased by 85  % from 2011 to 2012. From its peak use in 2007, the number of @entity1 filling a prescription decreased 97  %. A total of 1069 AEs were reported during the study period, of which 32 AE's were reported from Jan 2011 to Dec 2012. The average monthly reporting rates of AE's, SAE's and @entity299 's over 2011-2012 were 10.8/100,000 @entity1 , 9.1/100,000 @entity1 and 5.0/100,000 @entity1 , respectively. CONCLUSIONS: The utilization of RCP in Canada has significantly declined. The significance of the adverse event rate information presented is uncertain and must be evaluated within the context of the well known factors that can influence AE reporting rates, as well as limitations to the methods used to estimate these reporting rates.

XXXX use and associated adverse event rates in Canada: an updated analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity6170 :: ('MESH:C089730', 'Chemical') :: ['rosiglitazone'] @entity299 :: ('MESH:D006331', 'Disease') :: ['CAE', 'cardiac adverse events']
@entity6170 :: (MESH:C089730,Chemical) :: ['Rosiglitazone']
